J. Davies

发表

Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity

A. Parker, A. Godkin, A. Gallimore, 2021, Immunology.

Uusi-Kerttula, H. et al. (2018) Ad5NULL-A20: a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer

R. Vile, P. Rizkallah, H. Uusi-Kerttula, 2018 .

Two Novel Human Cytomegalovirus NK Cell Evasion Functions Target MICA for Lysosomal Degradation

M. Weekes, P. Tomasec, C. Fielding, 2014, PLoS pathogens.

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications

J. Chester, A. Parker, D. Majhen, 2020, Cancer Gene Therapy.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus

J. Chester, E. Hudson, A. Parker, 2018, Oncotarget.

Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion

C. Fielding, R. Stanton, E. Wang, 2020, The Journal of general virology.

The GacS sensor kinase controls phenotypic reversion of small colony variants isolated from biofilms of Pseudomonas aeruginosa PA14.

Lyriam L. R. Marques, H. Ceri, R. Turner, 2007, FEMS microbiology ecology.

Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5NULL-A20

H. Uusi-Kerttula, J. Chester, A. Parker, 2021, Viruses.

Efficient Intravenous Tumor Targeting Using the αVβ6 Integrin Selective Precision Virotherapy Ad5NULL-A20

H. Uusi-Kerttula, J. Chester, A. Parker, 2021 .

Human cytomegalovirus UL 141 promotes efficient downregulation of the natural killer cell activating ligand CD 112

P. Tomasec, R. Stanton, G. Wilkinson, 2010 .

The Novel Oncolytic Adenoviral Mutant Ad5-3 D -A20T Retargeted to a v b 6 Integrins Ef ﬁ ciently Eliminates Pancreatic Cancer Cells

A. Parker, L. Coughlan, Y. Man, 2018 .

Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors

R. Vile, C. Wetmore, A. Parker, 2020, Neuro-oncology.

Short Communication Human cytomegalovirus suppresses Fas expression and function

P. Tomasec, C. Fielding, G. Wilkinson, 2014 .

I-labelled oncolytic adenoviral mutants in models of pancreatic cancer

Julie, A. Parker, J. Sosabowski, 2020 .

Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer

A. Parker, J. Sosabowski, J. Foster, 2019, Scientific Reports.

Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group.

P. Collins, D. Bowen, L. S. Hathaway, 2007, Blood.

The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13.

D. Bowen, J. Davies, James A. Davies, 2007, Haematologica.

An association between the L 1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS 13

D. Bowen, J. Davies, James A. Davies, 2007 .

Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells

R. Stanton, A. Parker, R. Hargest, 2020, Clinical Cancer Research.

Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor

P. Rizkallah, A. Parker, J. Davies, 2019, bioRxiv.

The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism

P. Rizkallah, A. Parker, D. Cole, 2020, Journal of Virology.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies

R. Stanton, H. Uusi-Kerttula, J. Chester, 2015, Human gene therapy.

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions

P. Rizkallah, H. Uusi-Kerttula, A. Parker, 2018, Nature Communications.

Human cytomegalovirus suppresses Fas expression and function

P. Tomasec, C. Fielding, G. Wilkinson, 2014, The Journal of general virology.

Human adenovirus type 26 uses sialic acid–bearing glycans as a primary cell entry receptor

P. Rizkallah, A. Parker, J. Davies, 2019, Science Advances.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies

R. Vile, P. Rizkallah, H. Uusi-Kerttula, 2018, Clinical Cancer Research.

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies

H. Uusi-Kerttula, J. Chester, A. Parker, 2016, Oncotarget.

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications

H. Uusi-Kerttula, A. Parker, S. Hulin-Curtis, 2015, Viruses.

Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.

P. Tomasec, R. Stanton, G. Wilkinson, 2010, The Journal of clinical investigation.

Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation

S. Gygi, J. Trowsdale, J. Paulo, 2017, eLife.

Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112

P. Tomasec, R. Stanton, G. Wilkinson, 2010, The Journal of general virology.

Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions

Edward L. Huttlin, E. Huttlin, M. Weekes, 2019, eLife.

Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses

M. Weekes, P. Tomasec, C. Fielding, 2018, Proceedings of the National Academy of Sciences.

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells

A. Parker, L. Coughlan, J. Marshall, 2018, Molecular Cancer Therapeutics.